cat 255 sc cf Search Results


stem cell factor scf  (R&D Systems)
96
R&D Systems stem cell factor scf
Stem Cell Factor Scf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/bio_rxiv__2021__12__08__471791-224-27-33?v=R%26D+Systems
Average 96 stars, based on 1 article reviews
stem cell factor scf - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
recombinant human rscube3 protein  (R&D Systems)
93
R&D Systems recombinant human rscube3 protein
Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with <t>rSCUBE3</t> results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.
Recombinant Human Rscube3 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/pm36138226-250-13-20?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
recombinant human rscube3 protein - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
sc medium  (Valiant Co Ltd)
97
Valiant Co Ltd sc medium
Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with <t>rSCUBE3</t> results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.
Sc Medium, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/pmc10495264-239-10-32?v=Valiant+Co+Ltd
Average 97 stars, based on 1 article reviews
sc medium - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier
recombinant human stem cell factor r d systems  (R&D Systems)
93
R&D Systems recombinant human stem cell factor r d systems
Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with <t>rSCUBE3</t> results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.
Recombinant Human Stem Cell Factor R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/pmc10694620__mmc3-367-152-157?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
recombinant human stem cell factor r d systems - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
anti grb2  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology anti grb2
Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with <t>rSCUBE3</t> results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.
Anti Grb2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/pmc04135555-135-9-29?v=Santa+Cruz+Biotechnology
Average 96 stars, based on 1 article reviews
anti grb2 - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
protein 2  (Santa Cruz Biotechnology)
92
Santa Cruz Biotechnology protein 2
Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with <t>rSCUBE3</t> results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.
Protein 2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/pm32010245-82-280-331?v=Santa+Cruz+Biotechnology
Average 92 stars, based on 1 article reviews
protein 2 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
cytokines  (R&D Systems)
93
R&D Systems cytokines
Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with <t>rSCUBE3</t> results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.
Cytokines, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/bio_rxiv__2023__08__09__552676-264-45-53?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
cytokines - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
recombinant human scf  (R&D Systems)
97
R&D Systems recombinant human scf
Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with <t>rSCUBE3</t> results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.
Recombinant Human Scf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/pm38388899-38-0-8?v=R%26D+Systems
Average 97 stars, based on 1 article reviews
recombinant human scf - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier
anti rabbit  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology anti rabbit
Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with <t>rSCUBE3</t> results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.
Anti Rabbit, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/ppr0476941-106-4-15?v=Santa+Cruz+Biotechnology
Average 96 stars, based on 1 article reviews
anti rabbit - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
scf  (R&D Systems)
95
R&D Systems scf
Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with <t>rSCUBE3</t> results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.
Scf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/pm29377004-421-49-50?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
scf - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
cc ep te d m nu sc rip t 19 propidium iodide  (Valiant Co Ltd)
95
Valiant Co Ltd cc ep te d m nu sc rip t 19 propidium iodide
Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with <t>rSCUBE3</t> results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.
Cc Ep Te D M Nu Sc Rip T 19 Propidium Iodide, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/pm29319535-218-60-75?v=Valiant+Co+Ltd
Average 95 stars, based on 1 article reviews
cc ep te d m nu sc rip t 19 propidium iodide - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
human scf r d systems  (R&D Systems)
94
R&D Systems human scf r d systems
Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with <t>rSCUBE3</t> results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.
Human Scf R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cat+255+sc+cf/pm37426764-447-194-196?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
human scf r d systems - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

Image Search Results


Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with rSCUBE3 results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.

Journal: Cell death and differentiation

Article Title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.

doi: 10.1038/s41418-022-01031-x

Figure Lengend Snippet: Fig. 5 SCUBE3 regulates osteoclast formation. A Representative photomicrographs on day 9 of osteoclasts generated from monocytes; treatment with rSCUBE3 results in fewer osteoclasts identifed by TRAP and vitronectin receptor (VNR) staining. B Dose-dependent inhibition of the total number of TRAP-positive osteoclasts by rSCUBE3; number relative to day 9 control cultures; 5 osteoclast preparations. C Quantification of number of nuclei per osteoclast following treatment with 1.25 μg/ml rSCUBE3, expressed as a proportion of OCs exhibiting 3–5 or ≥6 nuclei over the total number of OCs; 5 osteoclast preparations. D Number of osteoclasts generated in the presence of conditioned medium (CM) from differentiated (day 6) hFOBs in the presence or absence of 1.25 μg/ml rSCUBE3 (relative number to control H3.3WT CM); 20 osteoclast preparations. Data represent the mean ± SEM. B, C: 2-way RM ANOVA. D: 1-way ANOVA.

Article Snippet: Effects of rSCUBE3 were investigated by treatment of osteoclast cultures with 0.25–1.25 μg/ml recombinant human rSCUBE3 protein (Cat # 7730-SC, R&D Systems, Abingdon, UK) in the presence of RANKL and M-CSF; all the reagents were replaced at each media change for osteoclasts.

Techniques: Generated, Staining, Inhibition, Control